Differentiating Anti-NMDA receptor encephalitis from other diseases: Difference between revisions
| Line 30: | Line 30: | ||
| 30–80 (60) 1:2 | | 30–80 (60) 1:2 | ||
| | | 46–77 (60) 1:4 | ||
| 38–87 (60) 9:1 | |||
| 24–75 (62) 1:1 | |||
| 5–69 (43) 6:5 | |||
| 46, 15 1:1 | |||
|- | |- | ||
| | | Clinical syndrome | ||
| | | 1.Prodromal Syndrome | ||
2. Psychiatric Syndrome, seizures, amnesia | |||
3.Movement disorders catatonia, autonomic instability, | |||
|Limbic encephalitis, tonic or facio-brachial dystonic seizures, | |||
myoclonus | |||
Revision as of 10:57, 21 January 2023
|
Anti-NMDA receptor encephalitis Microchapters |
|
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Differentiating Anti-NMDA receptor encephalitis from other diseases On the Web |
|
American Roentgen Ray Society Images of Differentiating Anti-NMDA receptor encephalitis from other diseases |
|
FDA on Differentiating Anti-NMDA receptor encephalitis from other diseases |
|
CDC on Differentiating Anti-NMDA receptor encephalitis from other diseases |
|
Differentiating Anti-NMDA receptor encephalitis from other diseases in the news |
|
Blogs on Differentiating Anti-NMDA receptor encephalitis from other diseases |
|
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;AE Dheeraj Makkar, M.D.[2]
Overview
Differentiating Anti-NMDA Receptor Encephalitis from other Diseases
| Antigen | NMDA receptor NR1 | Lgil | CASPR2 | AMPA receptor | GABA B receptor | Glycine receptor | MgluR5
|
|---|---|---|---|---|---|---|---|
| Age(median)/gender female : male | 0·6–85 (21) 4:1 | 30–80 (60) 1:2 | 46–77 (60) 1:4 | 38–87 (60) 9:1 | 24–75 (62) 1:1 | 5–69 (43) 6:5 | 46, 15 1:1 |
| Clinical syndrome | 1.Prodromal Syndrome
2. Psychiatric Syndrome, seizures, amnesia 3.Movement disorders catatonia, autonomic instability, |
Limbic encephalitis, tonic or facio-brachial dystonic seizures,
myoclonus
|
row 2, cell 3 |